The Majority Of Oncologists Will Begin Using Biosimilar Monoclonal Antibodies ...

31-10-2013 PR NewswireComments (0)


BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European oncologists will cautiously adopt biosimilar ...

Read more on PR Newswire

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top